CA2930735A1 - Tetracyclic autotaxin inhibitors - Google Patents

Tetracyclic autotaxin inhibitors Download PDF

Info

Publication number
CA2930735A1
CA2930735A1 CA2930735A CA2930735A CA2930735A1 CA 2930735 A1 CA2930735 A1 CA 2930735A1 CA 2930735 A CA2930735 A CA 2930735A CA 2930735 A CA2930735 A CA 2930735A CA 2930735 A1 CA2930735 A1 CA 2930735A1
Authority
CA
Canada
Prior art keywords
compound
pyrido
substituted
imidazo
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2930735A
Other languages
English (en)
French (fr)
Inventor
John Howard Hutchinson
David Lonergan
Martin Rowbottom
Andiliy Gokching Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sabre Therapeutics LLC
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of CA2930735A1 publication Critical patent/CA2930735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2930735A 2013-11-22 2014-11-20 Tetracyclic autotaxin inhibitors Abandoned CA2930735A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907947P 2013-11-22 2013-11-22
US61/907,947 2013-11-22
US201462038093P 2014-08-15 2014-08-15
US62/038,093 2014-08-15
PCT/US2014/066705 WO2015077502A1 (en) 2013-11-22 2014-11-20 Tetracyclic autotaxin inhibitors

Publications (1)

Publication Number Publication Date
CA2930735A1 true CA2930735A1 (en) 2015-05-28

Family

ID=53180151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2930735A Abandoned CA2930735A1 (en) 2013-11-22 2014-11-20 Tetracyclic autotaxin inhibitors

Country Status (17)

Country Link
US (2) US9926318B2 (enExample)
EP (1) EP3071569A4 (enExample)
JP (1) JP2016537388A (enExample)
KR (1) KR20160088878A (enExample)
CN (1) CN105764903B (enExample)
AU (1) AU2014352887A1 (enExample)
BR (1) BR112016010221A2 (enExample)
CA (1) CA2930735A1 (enExample)
CL (1) CL2016001232A1 (enExample)
CR (1) CR20160290A (enExample)
EA (1) EA201690880A1 (enExample)
IL (1) IL245389A0 (enExample)
MX (1) MX2016006688A (enExample)
NI (1) NI201600070A (enExample)
PE (1) PE20160902A1 (enExample)
PH (1) PH12016500863A1 (enExample)
WO (1) WO2015077502A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
HRP20210957T1 (hr) 2013-11-22 2021-09-17 Sabre Therapeutics Llc Spojevi inhibitori autotaksina
US9926318B2 (en) 2013-11-22 2018-03-27 Pharmakea, Inc. Tetracyclic autotaxin inhibitors
EP4026549A1 (en) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin inhibitors and uses thereof
US10730878B2 (en) * 2015-07-11 2020-08-04 Advenchen Pharmaceuticals, LLC Fused quinoline compounds as PI3K/mTOR inhibitors
CN105021735B (zh) * 2015-07-21 2017-09-19 中国科学院西北高原生物研究所 白刺种子或其提取物中ss和rsMTCA的检测方法
US20250002505A1 (en) * 2021-10-05 2025-01-02 Turning Point Therapeutics, Inc. Synthesis of macroyclic compounds
CN119591596B (zh) * 2024-12-04 2025-10-17 沈阳药科大学 4,5-二氢-3H-吡咯并[2,3-c]喹啉-4-酮衍生物及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
ATE332903T1 (de) 2000-10-03 2006-08-15 Lilly Icos Llc Kondensierte pyridoindolderivate
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
CA2745041C (en) 2008-12-01 2017-08-22 Kai Schiemann 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
KR20120027177A (ko) 2009-04-02 2012-03-21 메르크 파텐트 게엠베하 오토탁신 저해제로서의 피페리딘 및 피라진 유도체
AU2010230646B2 (en) 2009-04-02 2015-11-26 Merck Patent Gmbh Heterocyclic compounds as autotaxin inhibitors
EA201101396A1 (ru) 2009-04-02 2012-09-28 Мерк Патент Гмбх Ингибиторы аутотаксина
WO2011002918A1 (en) 2009-06-30 2011-01-06 The University Of Memphis Research Foundation Novel diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
AU2011232058B2 (en) 2010-03-26 2016-09-08 Merck Patent Gmbh Benzonaphthyridinamines as autotaxin inhibitors
US9000025B2 (en) 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2012100018A1 (en) 2011-01-20 2012-07-26 University Of Tennessee Research Foundation Inhibitors of autotaxin
AU2012219251B2 (en) * 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
JP2013129632A (ja) * 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
WO2014031170A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
BR112015014372A8 (pt) 2012-12-19 2019-10-29 Novartis Ag inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
US9926318B2 (en) 2013-11-22 2018-03-27 Pharmakea, Inc. Tetracyclic autotaxin inhibitors
HRP20210957T1 (hr) 2013-11-22 2021-09-17 Sabre Therapeutics Llc Spojevi inhibitori autotaksina
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor

Also Published As

Publication number Publication date
IL245389A0 (en) 2016-06-30
EP3071569A1 (en) 2016-09-28
PE20160902A1 (es) 2016-09-04
WO2015077502A1 (en) 2015-05-28
EA201690880A1 (ru) 2016-12-30
HK1226074B (zh) 2017-09-22
EP3071569A4 (en) 2017-09-13
CR20160290A (es) 2016-09-28
CN105764903A (zh) 2016-07-13
AU2014352887A1 (en) 2016-06-09
BR112016010221A2 (pt) 2018-05-02
MX2016006688A (es) 2016-11-29
KR20160088878A (ko) 2016-07-26
US20180162859A1 (en) 2018-06-14
JP2016537388A (ja) 2016-12-01
PH12016500863A1 (en) 2016-07-18
CL2016001232A1 (es) 2017-02-03
US9926318B2 (en) 2018-03-27
CN105764903B (zh) 2018-09-18
US20160264575A1 (en) 2016-09-15
NI201600070A (es) 2016-09-21

Similar Documents

Publication Publication Date Title
US9926318B2 (en) Tetracyclic autotaxin inhibitors
AU2019213425B2 (en) Autotaxin inhibitor compounds
JP6898868B2 (ja) Ｈｐｋ１阻害剤およびそれを用いる方法
CA2475633C (en) Heteroaryl compounds useful as inhibitors of gsk-3
KR100441362B1 (ko) 혈관 형성 억제 활성을 갖는 프탈라진
ES2635030T3 (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
JP2020515538A (ja) Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
CN105461693B (zh) Crth2拮抗剂化合物及其用途
TW202039459A (zh) Alk5 抑制劑
US12371432B2 (en) Haloallylamine compounds and application thereof
JP2023502662A (ja) Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
CN110003192A (zh) 取代的氨基嘧啶类化合物及其使用方法和用途
CN104487434B (zh) 双环取代的嘧啶类化合物
CN115873000B (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
CN103374002A (zh) 磷酸二酯酶-5抑制剂
CN115697972A (zh) 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂
WO2014154168A1 (zh) 双环取代的嘧啶类pde-5抑制剂的前药
AU2024263032A1 (en) Mrgprx2 inhibitors and methods of use thereof
HK1226074A1 (en) Tetracyclic autotaxin inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191115

FZDE Discontinued

Effective date: 20220520

FZDE Discontinued

Effective date: 20220520